Dapagliflozin was shown to ameliorate renal fibrosis by inhibiting receptor-interacting protein 1 (RIP1), receptor-interacting protein 3 (RIP3), and mixed lineage kinase domain-like (MLKL)-mediated necroinflammation, as well as ERS mediated by the Wnt3α/β-catenin/glycogen synthase kinase-3β (GSK-3β) signaling pathway in UUO [78]. The gene discussed is RIPK1; the disease is renal fibrosis.